Oxford academics question NOAC’s safety

Two Oxford academics have called for more research into the the safety and efficacy of the anticoagulant rivaroxiban (Xarelto).

Dr Carl Heneghan and  Dr Kamal Mahtani, both professors of evidence-based medicine, want an independent reanalysis of the clinical study known as the ROCKET AF trial, which compared the bleeding risks of warfarin with rivaroxiban in patients with atrial fibrillation.

This call comes after an investigation published by